A Structured Approach to Inform a Preliminary Pricing Strategy

A biotech company was preparing to launch a new PET imaging agent for prostate cancer patients with suspected biochemical recurrence into the US market. While a high unmet need continued to exist in recurrent prostate cancer, challenges remained in communicating the value of—and gaining reimbursement for—radiochemical imaging agents. This case study shares the approach to a well-structured preliminary pricing strategy to mitigate these challenges and drive success for the product.

Get the case study

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.